These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26095933)

  • 1. Risk and Causes of Death in Patients After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy.
    Veselka J; Zemánek D; Jahnlová D; Krejčí J; Januška J; Dabrowski M; Bartel T; Tomašov P
    Can J Cardiol; 2015 Oct; 31(10):1245-51. PubMed ID: 26095933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients ≤ 50 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
    Veselka J; Krejčí J; Tomašov P; Jahnlová D; Honěk T; Januška J; Branny M; Zemánek D
    Can J Cardiol; 2014 Jun; 30(6):634-8. PubMed ID: 24882534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low occurrence of ventricular arrhythmias after alcohol septal ablation in high-risk patients with hypertrophic obstructive cardiomyopathy.
    Rigopoulos AG; Daci S; Pfeiffer B; Papadopoulou K; Neugebauer A; Seggewiss H
    Clin Res Cardiol; 2016 Nov; 105(11):953-961. PubMed ID: 27270758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy.
    Cuoco FA; Spencer WH; Fernandes VL; Nielsen CD; Nagueh S; Sturdivant JL; Leman RB; Wharton JM; Gold MR
    J Am Coll Cardiol; 2008 Nov; 52(21):1718-23. PubMed ID: 19007692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Noseworthy PA; Rosenberg MA; Fifer MA; Palacios IF; Lowry PA; Ruskin JN; Sanborn DM; Picard MH; Vlahakes GJ; Mela T; Das S
    Am J Cardiol; 2009 Jul; 104(1):128-32. PubMed ID: 19576333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival after transcoronary ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy (TASH): a 10 year experience.
    Kuhn H; Lawrenz T; Lieder F; Leuner C; Strunk-Mueller C; Obergassel L; Bartelsmeier M; Stellbrink C
    Clin Res Cardiol; 2008 Apr; 97(4):234-43. PubMed ID: 18071624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy.
    Lawrenz T; Obergassel L; Lieder F; Leuner C; Strunk-Mueller C; Meyer Zu Vilsendorf D; Beer G; Kuhn H
    Pacing Clin Electrophysiol; 2005 Apr; 28(4):295-300. PubMed ID: 15826262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy.
    Liebregts M; Vriesendorp PA; Mahmoodi BK; Schinkel AF; Michels M; ten Berg JM
    JACC Heart Fail; 2015 Nov; 3(11):896-905. PubMed ID: 26454847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy.
    Sorajja P; Valeti U; Nishimura RA; Ommen SR; Rihal CS; Gersh BJ; Hodge DO; Schaff HV; Holmes DR
    Circulation; 2008 Jul; 118(2):131-9. PubMed ID: 18591440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: Safe and Apparently Efficacious But Does Reporting of Aggregate Outcomes Hide Less-Favorable Results, Experienced by a Substantial Proportion of Patients?
    Cooper RM; Shahzad A; McShane J; Stables RH
    J Invasive Cardiol; 2015 Jul; 27(7):301-8. PubMed ID: 26136275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation.
    Kwon DH; Kapadia SR; Tuzcu EM; Halley CM; Gorodeski EZ; Curtin RJ; Thamilarasan M; Smedira NG; Lytle BW; Lever HM; Desai MY
    JACC Cardiovasc Interv; 2008 Aug; 1(4):432-8. PubMed ID: 19463341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periprocedural complications and long-term outcome after alcohol septal ablation versus surgical myectomy in hypertrophic obstructive cardiomyopathy: a single-center experience.
    Steggerda RC; Damman K; Balt JC; Liebregts M; ten Berg JM; van den Berg MP
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1227-34. PubMed ID: 25326737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile.
    Jensen MK; Prinz C; Horstkotte D; van Buuren F; Bitter T; Faber L; Bundgaard H
    Heart; 2013 Jul; 99(14):1012-7. PubMed ID: 23644300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy.
    Elliott PM; Gimeno Blanes JR; Mahon NG; Poloniecki JD; McKenna WJ
    Lancet; 2001 Feb; 357(9254):420-4. PubMed ID: 11273061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a comparison with general population.
    Veselka J; Krejčí J; Tomašov P; Zemánek D
    Eur Heart J; 2014 Aug; 35(30):2040-5. PubMed ID: 24464834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interventional treatment in hypertrophic cardiomyopathy].
    Gietzen FH; Schümmelfeder J; Neuser H; Brunn J; Schumacher B; Kerber S
    Herz; 2005 Mar; 30(2):102-10. PubMed ID: 15875098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.
    Vriesendorp PA; Schinkel AF; Van Cleemput J; Willems R; Jordaens LJ; Theuns DA; van Slegtenhorst MA; de Ravel TJ; ten Cate FJ; Michels M
    Am Heart J; 2013 Sep; 166(3):496-502. PubMed ID: 24016499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.
    Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Januska J; Krejci J; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg JM; Veselka J
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1134-1143. PubMed ID: 28595881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.